CovidVax

The latest info on
Covid-19 Vaccines

DistributionFull ListCategories

protein-basednucleic-acidviral-vectorvirusother

protein-based vaccines (72)

Coronavirus proteins are injected directly into the body. Fragments of proteins or protein shells that mimic the coronavirus’s outer coat can also be used.

Two types of vaccines:

Protein subunits: Most of these vaccines are focusing on the virus’ spike protein, or a key part of it called the receptor binding domain. In order to work, these vaccines might require multiple doses and also adjuvants (immune-stimulating molecules delivered alongside the vaccine). Vaccines against the SARS virus have been developed in this way for protecting monkeys, but they haven’t been tested in people.

Virus-like particles: These vaccines use empty virus shells to mimic the coronavirus structure, but they aren’t infectious, as they lack genetic material. They can trigger a strong immune response, but can be difficult to manufacture.

more details on this Nature article

Ready for distribution (1)

vaccine researcher country started
EpiVacCorona FBRI SRC VB VECTOR Russia March 2021
Latest updates on these vaccines:
Jan 19EpiVacCorona's efficacy study will be made public in February said the center director
Oct 14EpiVacCorona has become the second vaccine to be approved by Russian authorities
Aug 23EpiVacCorona appeared to be safe in early clinical trials and all volunteers had no side effects
Aug 22According to a Russian agency EpiVacCorona elicits an immune response after double administration

Testing on humans (24)

vaccine researcher country started people
on trial
Recomb. Novavax USA May 6
2020
48035
@ Ph. 3
Protein subunit FR2 Instituto Finlay de Vacunas Cuba Nov 2
2020
44960
@ Ph. 3
PD-VLP Medicago Canada Jul 10
2020
31710
@ Ph. 2-3
RBD-Dimer Anhui Zhifei Longcom Biopharma + Institute of Microbiology Chinese Academy of Sciences China Jun 22
2020
30216
@ Ph. 3
RBD West China Hospital Sichuan University China Aug 28
2020
5128
@ Ph. 2
CpG 1018 Medigen Vaccine Biologics Corp + NIAID Taiwan + USA Sep 01
2020
3745
@ Ph. 2
S protein Sanofi Pasteur + GSK France + UK Sep 3
2020
1160
@ Ph. 2
eVLP VBI Vaccines USA + Canada Feb 15
2021
780
@ Ph. 1-2
Protein subunit FR1 Instituto Finlay de Vacunas Cuba Oct 19
2020
736
@ Ph. 1-2
Recomb. Nanogen Pharma Biotech Vietnam Dec 10
2020
620
@ Ph. 1-2
RBD Biological E India Nov 16
2020
360
@ Ph. 1-2
VLP SpyBiotech + Serum Institute of India UK + India Aug 17
2020
280
@ Ph. 1-2
Recomb. SK Bioscience South Korea Jan 20
2021
260
@ Ph. 1-2
RBD+alum Center for Genetic Engineering and Biotech (CIGB) Cuba Dec 7
2020
212
@ Ph. 1-2
RBD Kentucky BioProcess. (British American Tobacco) USA Jul 31
2020
180
@ Ph. 1-2
Trimeric S protein Clover Biopharma China Jun 19
2020
150
@ Ph. 1
Recomb. Razi Vaccine and Serum Research Institute Iran Jan 29
2021
133
@ Ph. 1
fusion protein University Groningen + Akston Biosciences Netherlands + USA Jan 18
2021
130
@ Ph. 1-2
RBD+AgnHB Center for Genetic Engineering and Biotech (CIGB) Cuba Dec 7
2020
88
@ Ph. 1-2
S protein Adimmune Taiwan Aug 20
2020
70
@ Ph. 1
MVP Covaxx + University of Nebraska Medical Center (UNMC) USA Sep 1
2020
60
@ Ph. 1
single-dose S protein Vaxine + Flinders University Australia + UK Jun 30
2020
40
@ Ph. 1
single-dose peptides University Hospital Tuebingen Germany Sep 30
2020
36
@ Ph. 1
S protein Shionogi + UMN Pharma Japan 0
@ Ph. 
Latest updates on these vaccines:
Mar 08Soberana 02 started Phase 3 clinical trials Monday in the capital Havana with a population segment between 19 to 64 years of age
Feb 26Novavax and Takeda have finalized license agreement for Novavax's vaccine in Japan with Takeda already dosed the first participants in a Phase 1/2 clinical trial
Feb 22Novavax announced the enrollment of PREVENT-19 its Phase 3 study in the US and Mexico to evaluate safety and efficacy of the vaccine
Feb 07Cuban's vaccine Soberana 02 will start its Phase 3 trial in March by enrolling 42600 participants
Feb 05SK Bioscience said it has begun conducting clinical studies on two COVID-19 vaccine candidates
Feb 04Novavax announced the start of the rolling review process for authorization of its vaccine by multiple regulatory agencies
Feb 04SK has started enrollment in a Phase 1/2 clinical trial for its COVID-19 vaccine supported by BMGF and CEPI
Feb 02On Jan.29 Taiwan Ministry of Health and Welfare granted conditional approval to begin Phase 2 trials of COVAXX vaccine
Feb 01Clover's vaccine candidate data from its Phase 1 clinical trial evaluating safety and immunogenicity was published in The Lancet
Feb 01Clover and Dynavax announced the plan to start a global Phase 2/3 efficacy trial of its vaccine in the first half of 2021

Testing on animals (22)

vaccine researcher country started human
trials
Spike protein Axon Neuroscience Slovakia
Subunit FBRI SRC VB VECTOR Russia
Peptide Flow Pharma USA Apr
2020
gp-96 Heat Biologics (Zolovax) USA Apr
2020
Protein subunit IMV Canada Apr
2020
Q3
2020
VLP Icosavax USA Oct
2020
Spike-based Immuno Precise + LiteVax BV Canada + Holland Aug
2020
Protein subunit InnoMedica Switzerland
Protein subunit MOGAM Institute for Biomedical Research + GC Pharma Korea
Protein subunit Max-Planck Institute of Colloids and Interfaces Germany
oral Migal Research Institute Israel Feb
2020
Q3
2020
Protein subunit PDS Biotech USA
RBD Saiba Switzerland Mar
2020
Aug
2020
CiVax Soligenix + University of Hawaii at Manoa USA
Recomb. Sorrento Tx USA Mar
2020
S protein St. Petersburg Scientific Research Institute of Vaccines and Serums Russia Mar
2020
skin patch University of Pittsburgh USA Mar
2020
Jun
2020
S protein VIDO-InterVac Canada Apr
2020
Jan
2020
S protein Vabiotech Vietnam May
2020
Peptide Vaxil Bio Israel Mar
2020
S protein Verndari + University of California Davis USA Apr
2020
S protein WRAIR + USAMRIID USA Mar
2020
Latest updates on these vaccines:
Nov 03Vabiotech's vaccine has been tested on 12 rhesus macaques and trials are expected to last around a month
Nov 02Icosavax received $10 million grant from Bill&Melinda Gates Foundation to support their vaccine program through a Phase 1 trial
Oct 30Icosavax announced the launch of the company's COVID-19 vaccine program with preclinical data on its vaccine
Oct 16Scientists with the USAMRDC expect to begin Phase 1 clinical trials of WRAIR's vaccine in Q4 2020
Oct 08DPX-COVID-19 has the potential to improve the duration of the immune response and protect older adults and more vulnerable individuals
Sep 09Axon announced positive preclinical results confirming the efficacy of the vaccine on the live SARS-CoV-2 virus
Aug 26Verndari announced funding from BARDA to support development of Verndari's VaxiPatch technology
Aug 13HeatBio's vaccine showed robust T cell driven immune response in preclinical studies
Aug 05Canadian govt will contribute up to CA$4.75m to advance Phase 1 clinical trials of IMV's vaccine
Jul 28Soligenix published its preclinical immunogenicity studies showing positive results

In early development (25)

vaccine researcher country animal
trials
human
trials
S protein AJ Vaccines Denmark
eVLP ARTES Biotech Germany
cVLP AdaptVac (PREVENT-nCoV EU consortium) Denmark + Netherlands + Germany Q4
2020
S1 - Fc AnyGo Technology China
Heat stable subunit Applied Biotech Institute USA
S1 or RBD Baylor College of Medicine USA
OMV BiOMVis + University of Trento Italy
VLP Doherty Institute Australia
S protein EpiVax + University of Georgia USA
Ii-Key peptide Generex + EpiVax Canada + USA
VLP Imophoron + Bristol University UK
S protein Innovax + Xiamen University Netherlands + China + UK
Nano particle LakePharma USA
RBD-based Neovii + Tel Aviv University Switzerland + Israel
VLP OSIVAX France
S/M proteins OncoGen Romania
VLP Osaka University + BIKEN Japan
OMV Quadram Institute Bioscience UK
S protein Shionogi + NIID Japan Japan Dec 11
2020
Spike based University of Alberta Canada
Plant virus University of California San Diego USA
Dendritic cell-based University of Manitoba Canada
VLPs University of Sao Paulo Brasil
S protein Yisheng Biopharma China
Plant produced iBio + CC-Pharming USA + China
Latest updates on these vaccines:
Jan 12AdaptVac published in Nature Communications its preclinical studies showing strong virus neutralization for its virus like particle vaccine
Dec 16Shionogi has initiated a Japanese Phase 1/2 clinical trial of a prophylactic vaccine candidate for COVID-19
Nov 16PREVENT-nCoV consortium member AdaptVac announced that its vaccine has been successfully manufactured
Jul 08Osivax has received €30m from different EU institutions for its universal coronavirus inoculation
May 13TAU and Neovii have teamed up to develop a vaccine against COVID-19
May 08YishengBiopharma's vaccine is in preclinical trials
May 07QI researchers are working on a COVID-19 vaccine
May 06Bavarian Nordic has entered into agreement with AdaptVac to license its vaccine
May 05Baylor College Texas Children's Hospital and PATH will accelarate the development of a vaccine
Apr 28BiOMVis in collaboration with Trento University are working to develop a vaccine


contact | about | ©2020 CovidVax.org project